Design Therapeutics, Inc. (DSGN) Stock Score, Valuation & Financial Research

Design Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for DSGN

Design Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 11.97. These figures are a research snapshot, not a buy or sell recommendation.

What Design Therapeutics, Inc. does

Design Therapeutics, Inc. is a biopharmaceutical company in the preclinical phase that focuses on creating treatments for genetic conditions stemming from nucleotide repeat expansions. Its current pipeline targets Friedreich's Ataxia (FA), a severe, progressive, monogenic, and autosomal recessive disease. FA primarily impairs mitochondrial function across various organ systems, resulting in neurological, cardiac, and metabolic complications. Another significant area of development is Myotonic Dystrophy Type-1 (DM1). This is a progressive, dominantly inherited monogenic neuromuscular illness that impacts skeletal muscle, the heart, brain, and other bodily systems. Beyond these, the company is advancing its GeneTAC product candidate platform to address an array of other monogenic conditions caused by nucleotide repeat expansions. These include Fragile X syndrome, various spinocerebellar ataxias, amyotrophic lateral sclerosis (ALS), frontotemporal dementia, Huntington's disease, and spinobulbar muscular atrophy. Established in 2017, Design Therapeutics, Inc. maintains its headquarters in Carlsbad, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Design Therapeutics is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model focuses on the research and development of GeneTAC small-molecule therapeutic candidates, and it relies on capital raises and financial reserves to fund its ongoing clinical trials and operations.

Products and services

  • The company is developing GeneTAC molecules, a class of small-molecule gene targeted chimeras designed to address the underlying causes of inherited nucleotide repeat expansion mutations.

Brands and product families

  • GeneTAC — The company's proprietary platform of gene targeted chimera small molecules. Source

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company relies on third-party contract organizations for clinical trial management, manufacturing of drug candidates, and other research-related services. Source

Business strengths to evaluate

  • Proprietary GeneTAC platform technology Source

Business risks and research considerations

  • History of operating losses and lack of product revenue Source
  • Dependence on clinical trial success and regulatory approvals Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

DSGN financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 11.97
Market capitalization:
747.61M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -70.8M
Free cash flow:
USD -54.55M
Cash:
USD 12.91M
Total debt:
USD 2.03M
EPS:
USD -1.18

What stands out

  • Free cash flow is USD -54.55M, negative for the stored period.
  • The balance sheet shows USD 12.91M of cash versus USD 2.03M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a missing revenue history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 10.88M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for DSGN

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can DSGN fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is DSGN likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for DSGN to reach sustainable profitability?
  • What does the current missing revenue history warning mean for the reliability or interpretation of DSGN's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research DSGN

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.